explore -WSS

explore

author：comprehensive 2025-09-30 00:50:30 - browse：1578

illustration of a colorful DNA strand, partly broken into pieces. -- health coverage from STAT — Adobe

BALTIMORE — An ambitious effort to cure HIV with CRISPR genome editing fell short in an early clinical trial, investigators announced Friday morning.

In the study, run by Excision BioTherapeutics, researchers tried to use the gene editing tool to address a chief reason HIV has been so hard to cure. While antiviral drugs can clear patients of replicating virus, HIV is able to worm its way into a patients’ own DNA in certain cells. If the patient ever stops taking medicines, those cells start pumping out HIV particles and the infection roars back.

Researchers hoped they could send CRISPR to those cells and, by cutting the HIV DNA lurking there at two spots, slice out the virus. In the Phase 1 trial, investigators administered the treatment to five patients. They then took three of them off conventional antiviral treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Humana cuts profit projections as Medicare Advantage costs soar

hotspot

WSS

A disappointing year of Humira biosimilars

Prior authorization will have to move faster under new Biden rule

Key House Republican on health care plans exit from Congress

Readout LOUD podcast: How biotech is using artificial intelligence

Parkinson’s finding may lead to tests and, someday, treatments

Think you might have Covid

leisure time

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The surgeon had a dilemma only a Nazi medical text could resolve

BioMarin wins approval for gene therapy to treat hemophilia A

Prior authorization will have to move faster under new Biden rule

Moonlake's readout produced a cash windfall. Risks remain

AI generated plenty of interest at JPM but not a lot of trust

Affirmative action in medical school literally saved lives

Medicare Advantage today, explained in one chart

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Biden report: The neurospychology of memory and aging

hotspot

'Revelatory' study finds a smoking impact that remains after quitting

Parkinson’s finding may lead to tests and, someday, treatments

Medicare Advantage today, explained in one chart

Gilead might be held responsible for not developing a drug

Medicare threatens to cut off funding for HCA's Mission hospital

Medicare Advantage proposed rates disappoint insurers

focus

Wikipedia

hotspot

Wikipedia